4. Ellison D, Sharppe R, Robbins B, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84:4310-5. 5. Konwalinka G, Schirmer M, Hilbe W, et al. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine. Blood Cells Mol Dis 1995; 21: 142-51. 6. Sarmiento M, Scolnik M, Narbaitz...

In this issue of Blood, Dietrich et al report that the low-dose BRAF inhibitor, vemurafenib, is highly effective in refractory hairy cell leukemia. Despite enormous progress that has been made with purine nucleoside analogs as the initial treatment of patients with hairy cell leukemia, the relapse rate and eventual development of refractory disease mandate the continued search for effective new...

Hairy cell leukemia and Sweet syndrome are both uncommon hematological diagnoses. We present a patient who was admitted with fevers, pancytopenia, pneumonia, and rash. Diagnostic bone marrow biopsy demonstrates Hairy cell Leukemia and skin biopsy demonstrates neutrophils infiltration consistent with Sweet syndrome. The patient was treated with purine analogs with resolution of the cytopenias, i...

Abbreviations: DLBL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MALT, MALT type lymphoma; MCL, mantle cell lymphoma; NMZL, nodal marginal zone B-cell lymphoma; PCR, polymerase chain reaction; SLL, small lymphocytic lymphoma; WHO, World Health Organization. sentation of hairy cell leukemia: a case series of four clinically unsuspected cases. Indian J Hematol Blood Transfus 2014;30(S...

: Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of non-Hodgkin's (NHL), characterized by poor outcome, accounting approximately for 10%-15% all non-Hodgkin in the western countries, and with higher prevalence Asia. Cyclin D1 immunoreactivity is characteristically seen mantle cell lymphoma. It also observed hairy leukemia, plasma myeloma proportion diffuse large B-cell lymp...

Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which BRAF V600E kinase–activating mutation plays pathogenetic role. In clinical trials involving patients with refractory or relapsed HCL, the targeting of oral inhibitor vemurafenib led to response 91% patients; 35% had complete response. However, median relapse-free survival was only 9 months after treatment stopped.

Although the coexistence of hairy cell leukemia with sarcoidosis has been reported in a few cases in the literature, in our case the patient had been diagnosed and followed about 10 years with sarcoidosis and massive splenomegaly. It has been demonstrated that T helper 1 cells exist in organs influenced by sarcoidosis. These cells produce IL-2 and IFN-γ and induce a nonspecific inflammatory res...

Cells from hairy cell leukemia (HCL) and hairy cell leukemia variant (HCL-V) have a distinct immunophenotype which is of a mature but not terminally differentiated activated B-cell. Although some similarities exist between these two conditions like the expression of B-cell activation marker CD103, CD11c and IgG heavy chain expression, differences exists between these two diseases. HCL is positi...

The diagnosis of hairy cell leukemia was made in three patients by phase-contrast microscopy and histochemistry of the abnormal peripheral blood cells. Both IgM and IgD surface immunoglobulins were resynthesized after these cells were trypsinized and cultured. Aggregate or Fc receptors were demonstrated on hairy cells. The ability to phagocytose latex was also a property of hairy cells; however...